This study will evaluate whether, compared to placebo, aripiprazole increases the time to relapse to cocaine use in abstinent polydrug users in methadone maintenance therapy. Based on a the results of studies with aripiprazole in a preclinical model of relapse, we hypothesize that aripiprazole will reduce relapse to cocaine use.
Participants receive aripiprazole (orally, up to 15 mg/day) plus standard methadone maintenance (daily oral methadone and weekly individual counseling).
2: Placebo Comparator
Drug: placebo
Participants receive identical capsules containing no active medication plus standard methadone maintenance (daily oral methadone and weekly individual counseling).
Eligibility
Ages Eligible for Study:
18 Years to 60 Years
Genders Eligible for Study:
Both
Accepts Healthy Volunteers:
No
Criteria
Inclusion Criteria:
physical dependence on opioids
seeking treatment for opiate and cocaine use
current cocaine use or dependence
Exclusion Criteria:
any medical or psychiatric condition that would compromise participation or contraindicated by study interventions
allergy or hypersensitivity to aripiprazole or methadone
pregnancy or breast-feeding
taking contraindicated medications
Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT00780702
